Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Earnings analysis
Iambic Therapeutics, Inc. · IAM · Third quarter 2026

Iambic's Q3: AI-platform deals double revenue, but the clinic drives the burn

Collaboration revenue rose to $11.4M and pro forma cash reached about $455M after the IPO, while R&D and G&A spending climbed as Iambic moves three oncology assets toward and into the clinic.

16 Nov 2026 · CompePharma editorial
$11.4 million (vs $4.7 million in Q3 2025)Q3 2026 collaboration revenue
$34.1 million (vs $23.1 million)Q3 2026 R&D expenses
$38.5 million (vs $21.5 million)Q3 2026 net loss
approximately $100 millionYTD collaboration billings
approximately $252 millionCash and cash equivalents, Sept 30, 2026
approximately $455 millionPro forma cash and cash equivalents

The quarter in numbers

Iambic Therapeutics reported third-quarter 2026 collaboration revenue of $11.4 million ($11,351 thousand), against $4.7 million a year earlier. The company said the increase was primarily due to its discovery collaborations. The release excerpt shows no product sales.

Total operating expenses were $41.5 million, up from $27.3 million, leaving a loss from operations of $30.1 million versus $22.6 million. Net loss was $38.5 million, compared with $21.5 million in Q3 2025, or $(8.52) per share versus $(5.24). The per-share figures rest on 4,521,229 weighted-average shares, a count that predates the October IPO.

Net loss included a $10.4 million non-cash charge for the change in fair value of convertible notes. The company said the notes converted into common stock immediately before the IPO closed. By our arithmetic, excluding that charge, the net loss would be about $28.1 million. Interest income was $2.0 million, up from $1.2 million.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.

More CP+ Earnings analysisAll →
CP+ Earnings analysis
CorMedix Inc. · CRMD · Third quarter 2026

CorMedix Q3: Post-TDAPA DefenCath Reset Meets Heron Deal and a Suspended 2027 Outlook

$54.5 millionQ3 2026 consolidated revenue$17.2 millionDefenCath net revenue$14.7 millionQ3 2026 net loss

Consolidated revenue of $54.5M beat the consensus the company cited, but DefenCath pricing, a $3.1M adjusted EBITDA and suspended 2027 guidance leave Heron and REZZAYO carrying the story.

17 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
Alumis Inc. · ALMS · Third quarter 2026

Alumis posts narrower Q3 loss as NDA nears, but a lupus miss narrows envudeucitinib's path

$1.9 million (vs $2.1 million in Q3 2025)Q3 2026 collaboration revenue$80.8 million (vs $97.8 million)Q3 2026 R&D expenses$94.9 million (vs $110.8 million)Q3 2026 net loss

Lower R&D cut the quarterly net loss to $94.9M, with a psoriasis NDA still due in 4Q 2026 and cash guided into 4Q 2027, while the LUMUS Phase 2b missed in the overall population.

16 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
Ionis Pharmaceuticals Inc · IONS · Third quarter 2026

Ionis lowers TRYNGOLZA outlook to ~$50M as DAWNZERA and partners carry Q3

$243 million (vs $157 million)Q3 2026 total revenue$9 millionQ3 TRYNGOLZA net sales$37 millionQ3 DAWNZERA net sales

Ionis reaffirmed total revenue, operating loss and cash guidance, but cut 2026 TRYNGOLZA sales to about $50 million from $100-110 million as its first large-indication launch ramps more slowly.

16 Nov 2026 · CompePharma editorial